CClinicalTrials.gg
Enrolling by invitationNCT07353918Updated Jan 21, 2026

Low-Intensity Focused Ultrasound Neuromodulation for Epilepsy

An interventional study of Low-intensity Focused Ultrasound and Sham in Epilepsy (Treatment Refractory) and Epilepsy Comorbidities, sponsored by Carilion Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Carilion Clinic · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study is an invite only study looking at the effects of Low-Intensity Focused Ultrasound (LIFU) on epilepsy patients with implanted electrodes under the care of Dr. Shah.

Read the detailed description

This project will explore the use of Low-Intensity Focused Ultrasound (LIFU) as a non-invasive method to reduce seizures and potentially enhance cognitive functions in epilepsy patients. LIFU can target specific deep brain areas without surgery, offering an alternative to invasive procedures. The study focuses on patients who have an implanted Responsive Neurostimulation System (RNS). LIFU will be used to stimulate the entorhinal cortex, a brain region involved in both seizure activity and memory formation. Investigators are targeting the perforant pathway from EC to hippocampus, which primarily relies of layers II and III of EC. Therefore, this targeting will ensure that layers II and III of EC are within the beam profile of LIFU. During study visits, participant will receive non-invasive ultrasound stimulation in their brains. Investigators will measure seizure frequency and epileptic activity using the implanted RNS system to assess LIFU's effects for epilepsy. Neuropsychological and memory tests will be conducted before and after LIFU application to detect changes in cognitive functions. Investigators will compare results before and after stimulation to determine LIFU's effectiveness in reducing seizures and potentially improving memory or other cognitive functions.

02

Conditions studied

  • Epilepsy (Treatment Refractory)
  • Epilepsy Comorbidities

Keywords

  • LIFU
  • Neuromodulation
  • Seizure
03

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of medically refractory focal epilepsy of mesial temporal onset
  • RNS system implantation in the hippocampus
  • Prior MRI and CT of the head
  • Able to consent for themselves
  • Internet access

Exclusion criteria

Exclusion Criteria:

  • TBI (ongoing, or in the prior 6 months)
  • Currently pregnant or breastfeeding
  • Progressive diseases - such as autoimmune epilepsies or diagnosis of a progressive neurological disorder
  • Status epilepticus within one year of study start
  • History of suicidal ideation or attempts in the last 6 months
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    LIFU- real

    Low-intensity focused ultrasound will be applied to the entorhinal cortex in a pre/post design.

    Device: Low-intensity Focused Ultrasound

  • Sham comparator
    LIFU - Sham

    Sham Low-intensity focused ultrasound will be applied to the entorhinal cortex in a pre/post design.

    Device: Sham

Interventions

  • DeviceLow-intensity Focused Ultrasound

    focused ultrasound transducer.

  • DeviceSham

    Sham application of LIFU - energy blocked. Targeted to the same target as intervention.

05

What researchers measure

Primary outcomes

  1. Seizure Frequency

    Utilizing the implanted RNS system patient seizure frequency will be monitored over time following both real and sham intervention.

    Time frame: 6 months past their final research study visit

Secondary outcomes

  1. Report of Symptoms Questionnaires

    To evaluate the safety profile and tolerability of LIFU delivery, measured by a series questionnaires pre and post LIFU application evaluating symptoms and side-effects. Participants are asked to report any existing (pre) \& new (post) symptoms

    Time frame: Within session, approximately over a 3 hour period.

  2. Memory Encoding

    To evaluate the cognitive effects of LIFU delivery on memory, participants will be assessed for correct vs incorrect encoding (face/name pair shown, \& then queried after a distractor task). % correct will be assessed.

    Time frame: Within session, over approximately 3 hours.

  3. Working Memory Task

    To evaluate the cognitive effects of LIFU delivery on working memory, participants will be assessed for correct vs incorrect encoding (given a list of objects, asked to recall in smallest to largest order). % correct will be assessed.

    Time frame: Within session, over approximately 3 hours.

06

Study locations

1 site
  • Fralin Biomedical Research Institute at VTC
    Roanoke, Virginia 24016, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07353918
Lead sponsor
Carilion Clinic
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Oct 13, 2025
Primary completion
Dec 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Jan 21, 2026

Study contacts

Aashit Shah, MD
principal investigator · Carilion Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion